"Sumitomo Chemical and Sumitomo Pharma have entered into agreements to establish a joint venture dedicated to advancing research and development in the Sumitomo Chemical Group’s regenerative medicine and cell therapy business.
The newly formed joint venture, RACTHERA, will serve as the central entity driving innovation in this domain. Collaborating with Sumitomo Chemical, Sumitomo Pharma, and their CDMO joint venture, RACTHERA aims to accelerate business growth and deliver new treatment solutions to patients swiftly.
By leveraging Sumitomo Pharma’s extensive expertise and advanced technologies in iPS cell-derived cell therapies, developed through years of research and development, alongside Sumitomo Chemical’s capabilities in industrial engineering, analysis, evaluation, and quality management, the Group seeks to maximise synergies and strengthen its position in the field.
Together, the companies are committed to expediting the development and global expansion of the regenerative medicine and cell therapy business, with an ambition to scale it into a market valued at approximately 350 billion yen by the late 2030s.